The Clinical Impact Of Rivaroxaban To Chinese At Atrial Fibrillation Patients Results From A Simple Communication Tool
Value Health
.
2014 Nov;17(7):A497.
doi: 10.1016/j.jval.2014.08.1487.
Epub 2014 Oct 26.
Authors
L Yang
1
,
J J Wu
2
,
G Zhu
2
,
T Evers
3
Affiliations
1
Peking University, Beijing, China.
2
Bayer Healthcare Company Ltd., Beijing, China.
3
Bayer Pharma AG, Wuppertal, Germany.
PMID:
27201494
DOI:
10.1016/j.jval.2014.08.1487
No abstract available